Details of the Drug Reposition

General Information of This Drug (ID: DM78NWP)

Drug Name
Dostarlimab   DM78NWP
Drug Type
Antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Endometrial cancer DISW0LMR 2C76 Approved [1]
------------------------------------------------------------------------------------
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Neoplasm DISZKGEW 2A00-2F9Z Phase 3 [2]
------------------------------------------------------------------------------------
2 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Multiple myeloma DISEWP9B 2A83 Phase 2 [3]
Breast cancer DIS7DPX1 2C60-2C65 Phase 2 [4]
------------------------------------------------------------------------------------

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
2 ClinicalTrials.gov (NCT03981796) A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer (RUBY). U.S. National Institutes of Health.
3 ClinicalTrials.gov (NCT04126200) Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 5). U.S. National Institutes of Health.
4 ClinicalTrials.gov (NCT04837209) Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer (NADiR). U.S. National Institutes of Health.